Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27643053 | 0.89 | SMN1; SMN2 (0.58) | CA1CA2ALDH1A1NPSR1FFAR1 | |
| SCHEMBL7603233 | 0.86 | CA1 (0.50) | CA1CA2ALDH1A1NPSR1MAPT | |
| SCHEMBL9845455 | 0.82 | CA1 (0.70) | CA1CA2ALDH1A1NPSR1FFAR1 | |
| SCHEMBL11582128 | 0.81 | ALDH1A1 (0.52) | CA1CA2ALDH1A1 | |
| SCHEMBL69746 | 0.81 | FFAR1 (0.81) | CA1CA2FFAR1KEAP1LMNA | |
| Lithium Ion SCHEMBL28445902 | 0.81 | CA1 (0.68) | CA1CA2ALDH1A1NPSR1FFAR1 | |
| SCHEMBL19207331 | 0.81 | CA1 (0.68) | CA1CA2ALDH1A1NPSR1FFAR1 | |
| SCHEMBL1429021 | 0.81 | CA1 (0.68) | CA1CA2ALDH1A1NPSR1FFAR1 | |
| SCHEMBL4964212 | 0.81 | CA2 (1.00) | CA1CA2ALDH1A1NPSR1FFAR1 | |
| SCHEMBL164742 | 0.80 | CA2 (0.54) | CA2ALDH1A1FFAR1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104130247-B | Human T 2 R bitterness receptors and application thereof | 塞诺米克斯公司 | 2018-06-01 | — | — | CN | disclosed |
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-2456435-B1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | UNIV LELAND STANFORD JUNIOR (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| CN-104130247-A | Human T2R bitter taste receptors and the use thereof | SENOMYX INC | 2014-11-05 | — | — | CN | disclosed |
| CN-101828111-B | Human T2R bitter taste receptor and uses thereof | SENOMYX INC | 2014-07-23 | — | — | CN | disclosed |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| WO-2004009583-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | GARST MICHAEL E (US) | 2004-01-29 | — | — | WO | disclosed |
| EP-0330050-B1 | Special chemiluminescent acridine derivatives and their use in luminescence immunoassays | DADE BEHRING MARBURG GMBH (DE) | 2000-08-23 | — | — | EP | disclosed |
| US-6002007-A | Special chemiluminescent acridine derivatives and the use thereof in luminescence immunoassays | DADE BEHRING MARBURG GMBH (DE) | 1999-12-14 | — | — | US | disclosed |
| US-5879953-A | Special chemiluminescent acridine derivatives and the use thereof in luminescence immunoassays | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-03-09 | — | — | US | disclosed |
| US-5783696-A | Special chemiluminescent acridine derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-21 | — | — | US | disclosed |
| EP-0602524-A1 | Chemiluminescence marked sequences and their use in sequence testing | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-06-22 | — | — | EP | disclosed |
| EP-0330050-A2 | Special chemiluminescent acridine derivatives and their use in luminescence immunoassays | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-30 | — | — | EP | disclosed |
| US-4493885-A | DIFFUSION TRANSFER | FUJI PHOTO FILM CO., LTD. (JP) | 1985-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | CA1 643/4885CA2 320/4885ALDH1A1 397/4885 |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | CA1 708/4885CA2 203/4885ALDH1A1 2892/4885 |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | CA1 708/4885CA2 203/4885ALDH1A1 2892/4885 |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | SI, ATP6AP1, HRH2 | CA1 1642/4885CA2 1378/4885ALDH1A1 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.